Companies · ZBH
Zimmer Biomet
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 5, 2026
Zimmer Biomet raises FY2026 organic growth guidance to 2.25%-3.25% on hip strength, 53% U.S. technology growth, and ahead-of-plan sales force transition.
Zimmer Biomet delivered Q2 2026 net sales of $2.177 billion, growing 4.8% reported and 4.0% organic constant currency, with U.S. hips accelerating to 5.9% growth and the Technology & Data segment expanding 21.5% — both above internal expectations. Management raised full-year 2026 organic constant currency guidance to 2.25%-3.25% (from 1%-3%) and adjusted EPS to $8.47-$8.59 (from $8.40-$8.55), citing sales force specialization ahead of plan, robust capital equipment demand, and Paragon 28 sustaining mid-teens growth. The most consequential forward signal is the iodine-coated hip platform in Japan — generating 40% ASP premium, competitive conversions, and demand outpacing supply — with active FDA pathway discussions underway for U.S. approval.
Tone: bullishRevenue
$8.2B
ZBH 10-K · FY 2025
Employees
17,000
Revenue growth YoY
+7.2%
Founded
1927
Profile
ZBH 10-K Item 1 · Feb 20, 2026Zimmer Biomet is a global medical technology company that designs, manufactures, and markets orthopedic reconstructive products, sports medicine and extremities devices, and integrated digital and robotic surgical technologies. The company serves orthopedic and neurosurgeons across three regional segments — Americas, EMEA, and Asia Pacific — through direct and distributor-based sales channels. Its ROSA robotic platform and ZBEdge digital ecosystem are central to its technology differentiation strategy.
Read filing description ↓ Collapse description ↑
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic ('CMFT') products; bone cement; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives. We allocate resources to achieve our operating profit goals through three regional operating segments: the Americas; Europe, Middle East and Africa ('EMEA'); and Asia Pacific. The Americas operating segment is our largest, comprised principally of the U.S. The EMEA operating segment is our second largest, with France, Germany, Italy, Spain and the United Kingdom collectively accounting for approximately 50 percent of net sales in the region in 2025. The Asia Pacific segment includes key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong and Malaysia, with Japan being the largest market within this segment. Through our Technology & Data, Bone Cement and Surgical product category, we market a collective suite of our products and technologies as the ZBEdge Platform, which connects robotic and digital technologies together to collect data before, during and after surgery.
Primary products
- Persona Knee
- NexGen Knee Implants
- Vanguard Knee
- Oxford Partial Knee
- Taperloc Hip System
- Avenir Complete Hip System
Business segments
End markets
Geographies
Named customers
No individual customer accounted for more than 2 percent of our net sales for 2025.
Named competitors
“In the global markets for our knees, hips, and S.E.T. products, our major competitors include Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson), Stryker Corporation and Smith & Nephew plc.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Net sales increased 7.2 percent in 2025 compared to 2024, driven by the Paragon 28 acquisition, market growth, new product introductions and a favorable foreign currency effect of 0.8 percent.
The rest of ZBH is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.